Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 1

Management of laryngopharyngeal reflux with proton pump inhibitors

Authors Reimer C, Bytzer P

Published 8 February 2008 Volume 2008:4(1) Pages 225—233

DOI https://doi.org/10.2147/TCRM.S6862

Christina Reimer, Peter Bytzer

Department of Medical Gastroenterology, Køge University Hospital, Denmark

Abstract: There is a lack of consistent guidelines and consensus for the diagnosis of laryngopharyngeal reflux (LPR). A therapeutic trial with a proton pump inhibitor (PPI) has been suggested to identify patients with LPR. This review focuses on the current difficulties in diagnosing the disease and examines the evidence for the effectiveness of PPI therapy in suspected reflux-related laryngeal symptoms. Additionally, mode of action, safety, and tolerability of PPIs are described. A total of 7 placebo-controlled trials were identified and included in the review. All studies evaluated the effect of a PPI on symptoms and objective laryngoscopic findings in suspected LPR. Data from these trials show that PPI therapy is no more effective than placebo in producing symptom relief in patients suspected of LPR. Symptoms, laryngoscopic findings, or abnormal findings on pH monitoring will not predict response to PPI therapy. High placebo response levels suggest a much more complex and multifactorial pathophysiology of LPR than simple acid reflux. Further studies are needed to characterize subgroups of patients with reflux-associated laryngeal symptoms that might benefit from treatment with PPI. Future studies should use validated patient reported outcome measures with endpoints that represent a predefined clinically meaningful change in symptom scores.

Keywords: laryngopharyngeal reflux, proton pump inhibitor

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Serotonin receptor modulators in the treatment of irritable bowel syndrome

Mohammad Fayyaz, Jeffrey M Lackner

Therapeutics and Clinical Risk Management 2008, 4:41-48

Published Date: 8 February 2008

Why does the world need another rotavirus vaccine?

Richard L Ward, Monica M McNeal, A Duncan Steele

Therapeutics and Clinical Risk Management 2008, 4:49-63

Published Date: 8 February 2008

Trabectedin and its potential in the treatment of soft tissue sarcoma

Philippe A Cassier, Armelle Dufresne, Jean-Yves Blay, Jérôme Fayette

Therapeutics and Clinical Risk Management 2008, 4:109-116

Published Date: 8 February 2008

A review of solifenacin in the treatment of urinary incontinence

Ramandeep Basra, Con Kelleher

Therapeutics and Clinical Risk Management 2008, 4:117-128

Published Date: 8 February 2008

Advances in the use of topical imiquimod to treat dermatologic disorders

Francesco Lacarrubba, Maria Rita Nasca, Giuseppe Micali

Therapeutics and Clinical Risk Management 2008, 4:87-97

Published Date: 8 February 2008

A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI)

Lala M Dunbar, Derek M Tang, Robert M Manausa

Therapeutics and Clinical Risk Management 2008, 4:235-244

Published Date: 8 February 2008

Zoledronic acid in the management of metastatic bone disease

Thomas J Polascik, Vladimir Mouraviev

Therapeutics and Clinical Risk Management 2008, 4:261-268

Published Date: 8 February 2008

Factors affecting therapeutic compliance: A review from the patient’s perspective

Jing Jin, Grant Edward Sklar, Vernon Min Sen Oh, Shu Chuen Li

Therapeutics and Clinical Risk Management 2008, 4:269-286

Published Date: 8 February 2008